Kirsten Flowers
Director/Board Member at PMV PHARMACEUTICALS, INC.
Net worth: 89 914 $ as of 30/03/2024
Profile
Kirsten Flowers is currently an Independent Director at PMV Pharmaceuticals, Inc., a Director at ReForm Biologics LLC, a Director at Comera Life Sciences, Inc., and an Independent Director at Comera Life Sciences Holdings, Inc. She previously served as the Senior Vice President-Commercial Operations at Array BioPharma, Inc. from 2017 to 2019 and as the Chief Commercial & Corporate Strategy Officer at Kura Oncology, Inc. from 2020 to 2023.
Flowers received her undergraduate degree from the University of Arizona and her MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
KURA ONCOLOGY, INC.
0.01% | 30/03/2023 | 4,180 ( 0.01% ) | 89 159 $ | 30/03/2024 |
| 08/11/2023 | 22,199 ( 0.07% ) | 755 $ | 30/03/2024 | |
| 07/06/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Kirsten Flowers active positions
| Companies | Position | Start |
|---|---|---|
| PMV PHARMACEUTICALS, INC. | Director/Board Member | 04/01/2022 |
| COMERA LIFE SCIENCES HOLDINGS, INC. | Director/Board Member | 18/05/2022 |
ReForm Biologics LLC
 ReForm Biologics LLC BiotechnologyHealth Technology ReForm Biologics LLC develops formulation technologies for biotherapeutics molecules. It provides technologies that include Viscosity-reducing excipients, Stability-enhancing excipients, and Surfactant-replacing excipients. The company was founded by David S. Soane and Zachariah Jonasson and is headquartered in Cambridge, MA. | Director/Board Member | 20/09/2021 |
Comera Life Sciences, Inc.
 Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Director/Board Member | - |
Former positions of Kirsten Flowers
| Companies | Position | End |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | 26/01/2023 |
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 31/12/2018 |
Training of Kirsten Flowers
| University of Arizona | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| KURA ONCOLOGY, INC. | Health Technology |
| PMV PHARMACEUTICALS, INC. | Commercial Services |
| COMERA LIFE SCIENCES HOLDINGS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
ReForm Biologics LLC
ReForm Biologics LLC BiotechnologyHealth Technology ReForm Biologics LLC develops formulation technologies for biotherapeutics molecules. It provides technologies that include Viscosity-reducing excipients, Stability-enhancing excipients, and Surfactant-replacing excipients. The company was founded by David S. Soane and Zachariah Jonasson and is headquartered in Cambridge, MA. | Health Technology |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a private company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | Health Technology |
- Stock Market
- Insiders
- Kirsten Flowers
